It was a privilege to contribute to the Jake Javier interview with @CNN’s @drsanjaygupta which aired today. Jake continues to be an inspiration to all of us, almost ten years following his treatment with Lineage’s OPC1 cell transplant. Watch for more:

#ICYMI: The @SCISymposium brought together a powerful lineup of companies and researchers advancing spinal cord injury treatment. Event replays are now available: . Thank you to all who joined us: @LineageCell, @NervGenP, @NBiologic, @onwdempowered,

Thank you to @TrialsArena and @globaldataplc for reporting OpRegen® cell therapy 36-month Phase 1/2a study results for the treatment of geographic atrophy (GA) presented at @CTS_Tahoe 2025 event. Read more here: . #ReplaceandRestore #Ophthalmology #AMD |

Thank you to @OphthTimes for covering the OpRegen® cell therapy 36-month Phase 1/2a study results in geographic atrophy (GA) secondary to AMD. More here: #ReplaceandRestore #Ophthalmology #AMD | @CEO_Culley

Thank you to @RetinalPhys for covering long term clinical data following a single administration of OpRegen® cell therapy for the treatment of GA presented @CTS_Tahoe. We’re grateful to Christopher D. Riemann, MD, of Cincinnati Eye Institute and EyeCare Partners, for sharing

Thank you to @DDWJournal for reporting @LineageCell’s OpRegen® (RG6501) 36-month study data showing sustained benefits in geographic atrophy secondary to AMD. For more: . #ReplaceandRestore #Ophthalmology #AMD | @CEO_Culley

The @SCISymposium is happening now — discover how innovators are driving progress in spinal cord injury treatment. . Presenters include @LineageCell, @NervGenP, @NBiologic, @onwdempowered, @Paradromics, @SpiderwortBio, @synchroninc, @RUSHMedical,

The @SCISymposium kicks off tomorrow — don’t miss your chance to listen to leading companies advancing spinal cord injury research. . Presenters include @LineageCell, @NervGenP, @NBiologic, @onwdempowered, @Paradromics, @SpiderwortBio, @synchroninc,

We are 3 days away from the @SciSymposium hosted by @LineageCell and @ReeveFoundation. Investors can register and request their 1-on-1 meetings with participating companies: Presenters include @LineageCell, @NervGenP, @NBiologic, @onwdempowered,

RT @CEO_Culley: Getting Dr. Makary’s vision in-person, instead of from headlines, provided me with sincere and lasting optimism. His goals….

OpRegen® (RG6501) Phase 1/2a clinical study 36-month results in patients with #GeographicAtrophy (GA) secondary to age-related macular degeneration #AMD were featured at @CTS_Tahoe 2025 Summit. Read more: . @ArshadKhanani @CEO_Culley @GenentechEye $LCTX

.@LineageCell and @ReeveFoundation are excited to announce @Paradromics and @synchroninc as additional presenters for the 3rd Annual @SCISymposium! Presenters also include @LineageCell, @NervGenP, @onwdempowered, @PrecisionNeuro_, @SpiderwortBio,

The $LCTX team is excited to attend Clinical Trials at the Summit (CTS) 2025 this weekend. . Christopher D. Riemann, MD, of Cincinnati Eye Institute, an Eyecare Partners practice, will present 36-month data from the OpRegen® (RG6501) Phase 1/2a trial in

.@LineageCell and @ReeveFoundation are excited to announce the initial agenda for the 3rd Annual @SCISymposium! . Presenters are still being added. Reminder to investors to register and request your 1-on-1 meetings with participating companies today:

RT @CEO_Culley: I appreciate the messages I’ve received about our team. A few spouses have been called up, but everyone is safe. The team’s….

Registration is open for the 3rd Annual @SciSymposium. Investors now have an opportunity to connect directly with the teams which are driving innovation and next-generation therapies in SCI. Register and request your 1-on-1 meetings with participating companies today:

.@LineageCell & @ReeveFoundation are excited to announce registration for the 3rd Annual @SCIsymposium. Presenters: @NervGenP @NBiologic @onwdempowered @HCWCO @PrecisionNeuro_ @RUSHMedical @RWBaird @Umiamimedicine @RobertPaylor5 @KesslerFdn @AbilityLab

$LCTX is on the ground at the 2025 @ASIA_spine Scientific Meeting in Scottsdale, AZ, broadening awareness of our DOSED study for #SpinalCordInjury. More about the meeting: #SCI #ReplaceandRestore

.@ModernRetina highlights upcoming 36-month data from OpRegen® (RG6501) Phase 1/2a trial in GA, to be presented at @CTS_Tahoe 2025 by Dr. Riemann of Cincinnati Eye Institute. Read more: $LCTX #CTSRetina #CTS2025

$LCTX ’s @CEO_Culley appreciated the opportunity to participate in @MizuhoAmericas’ 2025 Neuro & Ophthalmology Summit, during a keynote panel led by Graig Suvannavejh, PhD, Senior Analyst, US Healthcare. Read more: #ReplaceandRestore